Biogen Raises Outlook As New MS Drug Again Tops Forecasts

Biogen Idec Inc on Wednesday reported a higher first-quarter profit as sales of its new Tecfidera multiple sclerosis drug extended a run of eclipsing Wall Street sales expectations, and the U.S. biotechnology company raised its full-year forecasts.